DRD1
ENSG00000184845
Target class
GPCR
Chromosome
5
Approved drugs
9
Clinical candidates (approved and in development)
12
- Approved drugs
- 9
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- No
- Other names
- D1R
- Target name
- DRD1
- Gene name
- Dopamine receptor D1
- Gene symbol
- DRD1
- Protein name
- D(1A) dopamine receptor (Dopamine D1 receptor)
- Gene biotype
- Protein coding
- Gene family
- Dopamine receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 11
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 31.54
- Tissue specificity (Gini)
- 0.836
- Tissue specificity (tau)
- 0.949
- KEGG gene identifiers
- hsa:1812
- Protein interaction confidence
- 0.849677
- Protein interaction partners
- 31
- R-HSA-390651
- R-HSA-418555
- End position
- 175444794
- Start position
- 175440027
- Chromosome
- 5
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein . Endoplasmic reticulum membrane
- Multi-pass membrane protein . Cell projection, cilium membrane
- Multi-pass membrane protein . Cell projection, dendrite . Cell projection, dendritic spine . Note=Transport from the endoplasmic reticulum to the cell surface is regulated by interaction with DNAJC14. .
- Cytosol
- Plasma membrane
- PubMed 23936473
- PubMed 26182404
- Tissue specificity (tau)
- 0.949474
- Expression inequality (Gini)
- 0.836031
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 31.54
- Brain - Caudate (basal ganglia)
- 29.46
- Brain - Putamen (basal ganglia)
- 22.5
- Brain - Frontal Cortex (BA9)
- 5.73
- Brain - Cortex
- 4.32
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)31.54
- Brain - Caudate (basal ganglia)29.46
- Brain - Putamen (basal ganglia)22.5
- Brain - Frontal Cortex (BA9)5.73
- Brain - Cortex4.32
- Brain - Anterior cingulate cortex (BA24)3.5
- Brain - Amygdala2.08
- Prostate1.17
- Lung1.08
- Bladder1.07
- Brain - Hippocampus1.05
- Artery - Aorta0.89
- Kidney - Medulla0.77
- Brain - Hypothalamus0.72
- Cervix - Endocervix0.71
- Cervix - Ectocervix0.62
- Vagina0.62
- Fallopian Tube0.61
- Nerve - Tibial0.6
- Adipose - Visceral (Omentum)0.58
- Brain - Cerebellum0.45
- Uterus0.44
- Small Intestine - Terminal Ileum0.4
- Artery - Tibial0.36
- Adrenal Gland0.35
And 29 more, listed on the interactive page.
- GO:0007187
- GO:0007189
- GO:0007191
- GO:0042417
- GO:0051281
- GO:0051584
- GO:0060158
- GO:0071870
- GO:0005886
- GO:0005929
- GO:0045211
- GO:0060170
- GO:0097648
- GO:0097730
- GO:0001588
- GO:0001965
- GO:0004952
- GO:0005515
- GO:0032795
- GO:0035240
- GO:1990763
neurodegeneration
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: neurodegeneration
- renal
- central nervous system
- cardiovascular
PubMed 28216264headache
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: headache
- renal
- central nervous system
- cardiovascular
PubMed 28216264convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: convulsions
- renal
- central nervous system
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- central nervous system
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased convulsions
- renal
- central nervous system
- cardiovascular
PubMed 28216264drug abuse/dependence
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: drug abuse/dependence
- renal
- central nervous system
- cardiovascular
PubMed 28216264dizziness
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: dizziness
- renal
- central nervous system
- cardiovascular
PubMed 28216264suicidal intent
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: suicidal intent
- renal
- central nervous system
- cardiovascular
PubMed 28216264catalepsy
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: catalepsy
- renal
- central nervous system
- cardiovascular
PubMed 28216264parkinsonism
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: parkinsonism
- renal
- central nervous system
- cardiovascular
PubMed 28216264increased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood pressure
- renal
- central nervous system
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- renal
- central nervous system
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urine excretion
- renal
- central nervous system
- cardiovascular
PubMed 28216264heart failure
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: heart failure
- renal
- central nervous system
- cardiovascular
PubMed 28216264increased arousal
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased arousal
- renal
- central nervous system
- cardiovascular
PubMed 28216264increased/decreased locomotor activity
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased locomotor activity
- renal
- central nervous system
- cardiovascular
PubMed 28216264depression
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: depression
- renal
- central nervous system
- cardiovascular
PubMed 28216264anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: anxiety
- renal
- central nervous system
- cardiovascular
PubMed 28216264psychosis
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: psychosis
- renal
- central nervous system
- cardiovascular
PubMed 28216264decreased locomotor activity
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased locomotor activity
- renal
- central nervous system
- cardiovascular
PubMed 28216264dyskinesia
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: dyskinesia
- renal
- central nervous system
- cardiovascular
PubMed 28216264nausea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: nausea
- renal
- central nervous system
- cardiovascular
PubMed 28216264fibrotic valvular heart disease
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: fibrotic valvular heart disease
- renal
- central nervous system
- cardiovascular
PubMed 28216264
abuse potential
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: abuse potential
- cardiovascular system
- central nervous system
PubMed 23197038nausea
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: nausea
- cardiovascular system
- central nervous system
PubMed 23197038depression
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: depression
- cardiovascular system
- central nervous system
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hDRD1, is one of one assay component(s) measured or calculated from the NVS_GPCR_hDRD1 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourcedizziness
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: dizziness
- cardiovascular system
- central nervous system
PubMed 23197038parkinsonian symptoms (tremors)
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: parkinsonian symptoms (tremors)
- cardiovascular system
- central nervous system
PubMed 23197038headaches
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: headaches
- cardiovascular system
- central nervous system
PubMed 23197038decreased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased blood pressure
- cardiovascular system
- central nervous system
PubMed 23197038dyskinesia
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dyskinesia
- cardiovascular system
- central nervous system
PubMed 23197038natriuresis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: natriuresis
- cardiovascular system
- central nervous system
PubMed 23197038vascular relaxation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: vascular relaxation
- cardiovascular system
- central nervous system
PubMed 23197038anxiety
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: anxiety
- cardiovascular system
- central nervous system
PubMed 23197038suicidal intent
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: suicidal intent
- cardiovascular system
- central nervous system
PubMed 23197038anti-emetic effects
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: anti-emetic effects
- cardiovascular system
- central nervous system
PubMed 23197038
Related records
Trials (68)
- A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
- A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
- A Drug Interaction Study of LY3154207 in Healthy Participants
- A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751
- A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery
- A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS
- A Study of LY3154207 in Healthy Participants
- A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
- A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
- A Study of LY3154207 on Sleep in Healthy Male Participants
- A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
- A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants
- A Study to Evaluate LY3154207 on the Brain of Healthy Participants
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
- A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers
- Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia
- An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery
- An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects
- Compassionate Use Study of Pergolide in Patients With Parkinson's Disease
Drugs (16)
- Amineptine Dopamine D1 and D2 receptor antagonist
- Amoxapine Dopamine receptor antagonist
- Ecopipam Dopamine D1 receptor antagonist
- Ergoloid Dopamine receptor agonist
- Ergoloid mesylates Dopamine receptor agonist
- Fenoldopam Dopamine D1 receptor agonist
- Fenoldopam mesylate Dopamine D1 receptor agonist
- Methylergonovine Dopamine D1 receptor antagonist
- Methylergonovine maleate Dopamine D1 receptor antagonist
- Mevidalen Dopamine D1 receptor positive allosteric modulator
- Minaprine Dopamine D1 and D2 receptor agonist
- Minaprine hydrochloride Dopamine D1 and D2 receptor agonist
- Pergolide Dopamine receptor agonist
- Pergolide mesylate Dopamine receptor agonist
- Pimozide Dopamine receptor antagonist
- Tavapadon Dopamine D1 receptor partial agonist